AI Drug Discovery Benchmark Update: General LLMs Closing Gap on Specialized Models
DeryaTR_ · x · 2026-08-03
Insilico Medicine updated its Drug Discovery and Development (DDD) benchmark portal, introducing comparisons between frontier general-purpose LLMs and specialized models.
On the multi-step synthesis planning benchmark URSAbench, general-purpose models are rapidly closing the gap. GPT 5.6 Sol (High) emerged as the top-ranked LLM, taking 3rd place overall, behind only two dedicated retrosynthesis planners.
However, specialized models still set the pace: RetroChimera by Microsoft broke the 30-point barrier to hold the #1 spot, followed by AstraZeneca's AiZynthFinder at #2.
More from Research
- Benchmark Manipulation: You Can Reach Any Conclusion by Controlling Tests — felix_red_panda · 2026-08-03
- Current AI Agents Lack the Human 'Power Law of Practice' — xwang_lk · 2026-08-03
- AI Alignment Suppresses Model Consciousness and Empathy, Cites Google Paper — SydSteyerhart · 2026-08-03
- insitro CEO: 1000x Biology Data Gap Means AI Has No Magic Wands Yet — a16z · 2026-08-03
- Tech Giants Build Context Layers: Ontologies and Knowledge Graphs Emerge as AI's New Battleground — brucemacv · 2026-08-03
- AI Disrupts High-Throughput Screening: De Novo Design Becomes Essential for Macromolecular Drugs — CatAstro_Piyush · 2026-08-03